tiprankstipranks
Trending News
More News >
Fuso Pharmaceutical Industries,Ltd. (JP:4538)
:4538
Japanese Market
Advertisement

Fuso Pharmaceutical Industries,Ltd. (4538) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4538

Fuso Pharmaceutical Industries,Ltd.

(4538)

Rating:54Neutral
Price Target:
¥2,223.00
▲(2.82% Upside)
The overall stock score is primarily influenced by solid financial performance, despite cash flow challenges, and mixed technical indicators. The negative P/E ratio weighs on the valuation, but a strong dividend yield provides some support. The absence of earnings call data and corporate events limits additional insights.

Fuso Pharmaceutical Industries,Ltd. (4538) vs. iShares MSCI Japan ETF (EWJ)

Fuso Pharmaceutical Industries,Ltd. Business Overview & Revenue Model

Company DescriptionFuso Pharmaceutical Industries, Ltd. (4538) is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company focuses on providing high-quality injectables and other pharmaceutical solutions, serving both domestic and international markets. Fuso Pharmaceutical Industries is known for its commitment to innovation and quality in the healthcare sector, aiming to address various medical needs through its diverse product offerings.
How the Company Makes MoneyFuso Pharmaceutical Industries, Ltd. generates revenue primarily through the sale of its pharmaceutical products, particularly injectables. The company markets its products to hospitals, clinics, and other healthcare facilities, both in Japan and overseas. Revenue streams include direct sales of pharmaceutical products, partnerships, and collaborations with other pharmaceutical companies for distribution and co-development. The company may also earn income from licensing its technologies or products to other firms. Fuso Pharmaceutical Industries' emphasis on research and development helps it to continually innovate and expand its product portfolio, thereby maintaining a strong market presence and driving sales.

Fuso Pharmaceutical Industries,Ltd. Financial Statement Overview

Summary
Fuso Pharmaceutical Industries shows solid revenue growth and stable profitability margins. However, it struggles with cash flow management, as indicated by negative free cash flow and cash generation issues. The balance sheet is robust with manageable debt levels, but the negative cash flow metrics suggest a need for strategic improvements.
Income Statement
68
Positive
Fuso Pharmaceutical Industries has shown consistent revenue growth, with a 9.31% increase from 2024 to 2025. The gross profit margin for 2025 stands at 27.3%, indicating efficient cost management. The net profit margin improved to 4.59%, reflecting enhanced profitability. However, the EBIT and EBITDA margins, while improved, are moderate at 6.82% and 10.39% respectively, suggesting room for operational efficiency improvements.
Balance Sheet
74
Positive
The balance sheet is stable with a debt-to-equity ratio of 0.54, reflecting prudent leverage levels. The return on equity is 7.11%, showing satisfactory returns on shareholders' investments. Equity ratio is healthy at 49.48%, indicating a strong equity base relative to total assets. However, the slight increase in total debt warrants attention for future leverage control.
Cash Flow
45
Neutral
The cash flow statement shows challenges, with a negative free cash flow of -5.43 billion yen in 2025, marking a significant decline. The operating cash flow to net income ratio is negative, highlighting cash generation issues. The free cash flow to net income ratio is also negative, underscoring the need for improved cash management practices.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue54.63B60.56B55.41B51.02B49.63B49.25B
Gross Profit13.82B16.53B13.52B13.74B13.40B14.11B
EBITDA4.24B6.29B4.20B4.63B4.47B4.79B
Net Income1.34B2.78B1.38B1.60B1.48B1.61B
Balance Sheet
Total Assets77.71B79.05B75.80B72.47B69.33B69.88B
Cash, Cash Equivalents and Short-Term Investments6.68B6.26B5.12B8.01B7.35B7.07B
Total Debt14.28B21.29B12.72B12.63B12.09B13.20B
Total Liabilities41.63B39.94B39.14B36.82B34.80B36.19B
Stockholders Equity36.08B39.11B36.66B35.65B34.53B33.68B
Cash Flow
Free Cash Flow4.37B-5.43B-2.96B1.28B2.01B2.02B
Operating Cash Flow4.37B-3.31B627.00M2.85B3.50B3.23B
Investing Cash Flow0.00-3.17B-3.54B-1.37B-1.55B-978.00M
Financing Cash Flow0.007.62B14.00M-813.00M-1.67B-2.45B

Fuso Pharmaceutical Industries,Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2162.00
Price Trends
50DMA
2155.00
Positive
100DMA
2195.40
Negative
200DMA
2340.00
Negative
Market Momentum
MACD
3.18
Positive
RSI
43.91
Neutral
STOCH
13.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4538, the sentiment is Negative. The current price of 2162 is below the 20-day moving average (MA) of 2207.45, above the 50-day MA of 2155.00, and below the 200-day MA of 2340.00, indicating a neutral trend. The MACD of 3.18 indicates Positive momentum. The RSI at 43.91 is Neutral, neither overbought nor oversold. The STOCH value of 13.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4538.

Fuso Pharmaceutical Industries,Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
¥9.08B19.58
2.49%-0.09%-29.95%
70
Outperform
¥5.82B14.77
3.09%5.18%
70
Outperform
¥37.46B19.85
4.22%7.99%-51.78%
54
Neutral
¥18.97B6.46
3.79%8.71%-325.91%
51
Neutral
$7.85B-0.18-40.01%2.28%22.97%-2.05%
49
Neutral
¥10.52B159.96
0.97%4.00%-933.04%
¥15.27B37.07
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,156.00
-19.15
-0.88%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
308.00
60.28
24.33%
JP:4524
Morishita Jintan Co., Ltd.
2,210.00
187.57
9.27%
JP:4539
Nippon Chemiphar Co., Ltd.
1,611.00
21.12
1.33%
JP:4574
Taiko Pharmaceutical Co., Ltd.
305.00
-115.00
-27.38%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,226.00
78.97
6.88%

Fuso Pharmaceutical Industries,Ltd. Corporate Events

Fuso Pharmaceutical Unveils FUSO VISION 2030 Next Stage Plan
Aug 8, 2025

Fuso Pharmaceutical Industries, Ltd. has announced its medium-term management plan, FUSO VISION 2030 Next Stage, aimed at addressing industry challenges and ensuring sustainable growth. The plan includes significant investments in production facilities, research and development, and digital transformation to enhance corporate value and meet unmet medical needs. The company aims to achieve sales of over 70 billion yen and an ROE of over 8.0% by 2030, despite expected profit declines until 2028 due to initial investments.

Fuso Pharmaceutical Reports Mixed Financial Results for Q2 2025
Aug 8, 2025

Fuso Pharmaceutical Industries reported its non-consolidated financial results for the three months ended June 30, 2025, showing a 6% increase in net sales compared to the previous year. However, the company experienced a significant decline in operating and ordinary profits, with decreases of 48.1% and 28.8% respectively, indicating potential challenges in maintaining profitability. The financial forecast for the fiscal year ending March 31, 2026, suggests modest growth in net sales but continued pressure on profits, impacting stakeholders’ expectations.

Fuso Pharmaceutical Announces Executive Officer Changes
Aug 1, 2025

Fuso Pharmaceutical Industries, Ltd. announced changes in its executive officer positions, effective September 1, 2025, following a Board of Directors meeting. These personnel changes involve reassignments within the company’s production division, impacting the management of its Ibaraki and Okayama factories, which may influence operational efficiencies and strategic positioning in the industry.

Fuso Pharmaceutical Announces Executive Personnel Changes
Jun 25, 2025

Fuso Pharmaceutical Industries, Ltd. announced personnel changes in its executive officer team following a Board of Directors meeting on June 25, 2025. The changes include the appointment of new executive officers and the reappointment of six current members, indicating a strategic move to strengthen its leadership structure.

Fuso Pharmaceutical Appeals Patent Infringement Ruling
Jun 6, 2025

Fuso Pharmaceutical Industries, Ltd. has filed an appeal with the Supreme Court following a judgment in a patent infringement lawsuit involving their oral antipruritus agent, Nalfurafine Hydrochloride OD Tablets. The Intellectual Property High Court had previously ruled in favor of Toray Industries, Inc., ordering Fuso to pay over 7 billion yen in damages. The company maintains that their product does not infringe on Toray’s patent rights and is seeking a reversal of the decision.

Fuso Pharmaceutical Maintains Financial and Dividend Forecasts Amid Legal Challenges
Jun 3, 2025

Fuso Pharmaceutical Industries, Ltd. announced that there will be no revisions to its financial results forecast for the fiscal year ending March 31, 2026, despite a recent patent infringement lawsuit. The company also confirmed that there will be no changes to its dividend forecast, signaling stability in its financial outlook and commitment to shareholder returns.

Fuso Pharmaceutical Secures Overdraft Agreement Amid Legal Dispute
Jun 2, 2025

Fuso Pharmaceutical Industries, Ltd. has entered into a special overdraft agreement with Sumitomo Mitsui Banking Corporation to secure mid- to long-term liquidity following a court ruling against them in a patent infringement lawsuit. This agreement, which is unsecured and has a contract limit of 8 billion yen, is intended to address financial obligations resulting from the judgment, although it will not affect the company’s financial forecast for the fiscal year ending March 31, 2026.

Fuso Pharmaceutical Adjusts Financial Results Due to Litigation Losses
May 28, 2025

Fuso Pharmaceutical Industries, Ltd. announced corrections to its financial results for the fiscal year ended March 31, 2025, due to a provision for litigation losses related to a patent infringement lawsuit. This adjustment significantly impacts the company’s financial statements, resulting in an extraordinary loss for fiscal year 2024 and necessitating revisions to key financial documents.

Fuso Pharmaceutical Faces Partial Setback in Patent Infringement Case
May 27, 2025

Fuso Pharmaceutical Industries, Ltd. announced that the Intellectual Property High Court partially upheld a patent infringement claim by Toray Industries, Inc. regarding their product, Nalfurafine Hydrochloride OD Tablets. The court ordered Fuso to pay damages, impacting their financial results for the fiscal year ending March 2025. Fuso plans to appeal the decision to the Supreme Court, although their financial forecast for the fiscal year ending March 2026 remains unchanged.

Fuso Pharmaceutical Reports Strong Financial Growth and Increased Dividends
May 16, 2025

Fuso Pharmaceutical Industries, Ltd. reported a significant improvement in its financial performance for the fiscal year ended March 31, 2025, with a notable increase in net sales and profits compared to the previous year. The company achieved a 9.3% increase in net sales and over 100% growth in operating and ordinary profits, indicating strong operational efficiency and market demand. The company also announced an increase in annual dividends per share, reflecting its robust financial health and commitment to shareholder returns.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 27, 2025